{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:00Z","timestamp":1786982760953,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40264-017-0526-1","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T06:55:21Z","timestamp":1490338521000},"page":"497-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-885X","authenticated-orcid":false,"given":"Andreas","family":"Schick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lanthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Dal Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"Nardinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,24]]},"reference":[{"issue":"3","key":"526_CR1","doi-asserted-by":"crossref","first-page":"e1001407","DOI":"10.1371\/journal.pmed.1001407","volume":"10","author":"R Duijnhoven","year":"2013","unstructured":"Duijnhoven R, Straus S, Raine J, Hoes A, De Bruin M. Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med. 2013;10(3):e1001407.","journal-title":"PLoS Med"},{"issue":"5","key":"526_CR2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1377\/hlthaff.27.5.w360","volume":"27","author":"S Reed","year":"2008","unstructured":"Reed S, Anstrom K, Sells D, Califf R, Schulman K. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. Health Affairs. 2008;27(5):360\u201370.","journal-title":"Health Affairs"},{"issue":"2","key":"526_CR3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1086\/368006","volume":"45","author":"M Olson","year":"2002","unstructured":"Olson M. Pharmaceutical policy and the safety of new drugs. J Law Econ. 2002;45(2):615\u201342.","journal-title":"J Law Econ."},{"issue":"6","key":"526_CR4","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhealeco.2004.03.007","volume":"23","author":"M Olson","year":"2004","unstructured":"Olson M. Are novel drugs more risky for patients than less novel drugs? J Health Econ. 2004;23(6):1135\u201358.","journal-title":"J Health Econ"},{"issue":"2","key":"526_CR5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jhealeco.2007.10.007","volume":"27","author":"M Olson","year":"2008","unstructured":"Olson M. The risk we bear: the effects of review speed and industry user fees on new drug safety. J Health Econ. 2008;27(2):175\u2013200.","journal-title":"J Health Econ."},{"issue":"2","key":"526_CR6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/589934","volume":"51","author":"H Grabowski","year":"2008","unstructured":"Grabowski H, Wang Y. Do faster Food and Drug Administration drug reviews adversely affect patient safety? An analysis of the 1992 Prescription Drug User Fee Act. J Law Econ. 2008;51(2):377\u2013406.","journal-title":"J Law Econ."},{"issue":"7","key":"526_CR7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrd1774","volume":"4","author":"E Berndt","year":"2005","unstructured":"Berndt E, Gottschalk A, Philipson T, Strobeck M. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nat Rev Drug Discov. 2005;4(7):545\u201354.","journal-title":"Nat Rev Drug Discov."},{"key":"526_CR8","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1056\/NEJMsa0706341","volume":"358","author":"D Carpenter","year":"2008","unstructured":"Carpenter D, Zucker E, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008;358:1354\u201361.","journal-title":"N Engl J Med."},{"issue":"1","key":"526_CR9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1540-5907.2011.00544.x","volume":"56","author":"D Carpenter","year":"2012","unstructured":"Carpenter D, Chattopadhyay J, Moffitt S, Nall C. The complications of controlling agency time discretion: FDA review deadlines and post-market drug safety. Am J Political Sci. 2012;56(1):98\u2013114.","journal-title":"Am J Political Sci."},{"key":"526_CR10","unstructured":"Guidance for Industry Expedited Programs for Serious Conditions\u2014Drugs and Biologics. U.S. Food and Drug Administration Center for Drug Evaluation and Research. \n                        http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM358301.pdf\n                        \n                    . Accessed 31 Jan 2017."},{"key":"526_CR11","unstructured":"CDER 21st Century Review Process Desk Reference Guide. U.S. Food and Drug Administration Center for Drug Evaluation and Research. \n                        http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/CDER\/ManualofPoliciesProcedures\/UCM218757.htm\n                        \n                    . Accessed 5 Oct 2016."},{"issue":"3","key":"526_CR12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/pds.3395","volume":"22","author":"J Lester","year":"2013","unstructured":"Lester J, Neyarapally G, Lipowski E, Graham C, Hall M, Dal Pan G. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf. 2013;22(3):302\u20135.","journal-title":"Pharmacoepidemiol Drug Saf."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0526-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0526-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0526-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T04:10:32Z","timestamp":1494907832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0526-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,24]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["526"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0526-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,24]]}}}